GEOVAX LAUNCHES TRIALS FOR HIV/AIDS VACCINE

A A

GeoVax has announced that its HIV/AIDS human clinical trials have begun at several sites around the U.S. The trials will include testing of both DNA and MVA components of an HIV/AIDS vaccine developed by a team of researchers at GeoVax, the Yerkes National Primate Research Center at Emory University and the Emory Vaccine Center, along with colleagues at the NIH and the CDC.

U.S. sites participating in the HIV Vaccine Trials Network include the University of Alabama at Birmingham, Saint Louis University, the University of Maryland and Vanderbilt University. Trials at these locations are being conducted with HIV-negative volunteers.